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Background: Calciﬁc aortic valve disease (CAVD) is the most common heart valve disease in the Western
world. We previously proposed that valvular endothelial cells (VECs) replenish injured adult valve
leaﬂets via endothelial-to-mesenchymal transformation (EndMT); however, whether EndMT contributes
to valvular calciﬁcation is unknown. We hypothesized that aortic VECs undergo osteogenic differentia-
tion via an EndMT process that can be inhibited by valvular interstitial cells (VICs).
Approach and results: VEC clones underwent TGF-b1-mediated EndMT, shown by signiﬁcantly increased
mRNA expression of the EndMT markers a-SMA (5.3 ± 1.2), MMP-2 (13.5 ± 0.6) and Slug (12 ± 2.1)
(p < 0.05), (compared to unstimulated controls). To study the effects of VIC on VEC EndMT, clonal
populations of VICs were derived from the same valve leaﬂets, placed in co-culture with VECs, and grown
in control/TGF-b1 supplemented media. In the presence of VICs, EndMT was inhibited, shown by
decreased mRNA expression of a-SMA (0.1 ± 0.5), MMP-2 (0.1 ± 0.1), and Slug (0.2 ± 0.2) (p < 0.05).
When cultured in osteogenic media, VECs demonstrated osteogenic changes conﬁrmed by increase in
mRNA expression of osteocalcin (8.6 ± 1.3), osteopontin (3.7 ± 0.3), and Runx2 (5.5 ± 1.5). The VIC
presence inhibited VEC osteogenesis, demonstrated by decreased expression of osteocalcin (0.4 ± 0.1)
and osteopontin (0.2 ± 0.1) (p < 0.05). Time course analysis suggested that EndMT precedes osteogenesis,
shown by an initial increase of a-SMA and MMP-2 (day 7), followed by an increase of osteopontin and
osteocalcin (day 14).
Conclusions: The data indicate that EndMT may precede VEC osteogenesis. This study shows that VICs
inhibit VEC EndMT and osteogenesis, indicating the importance of VECeVIC interactions in valve
homeostasis.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).EC, valvular endothelial cell;
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Calciﬁc aortic valve disease (CAVD) and subsequent aortic valve
stenosis is the most common heart valve disease in the Western
world [1,2]. CAVD is currently considered an actively regulated and
progressive disease, characterized by a cascade of cellular changes
that initially cause ﬁbrotic thickening, followed by extensive
calciﬁcation of the aortic valve leaﬂets. This in turn leads to sig-
niﬁcant aortic valve stenosis and eventual left ventricular outﬂow
obstruction [3,4], for which surgical replacement remains the only
viable treatment option.
Heart valves contain a heterogeneous population of valvulararticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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maintain valve homeostasis and structural leaﬂet integrity. VICs,
the most abundant cell type in the heart valve, play a key role in
CAVD progression. Various VIC phenotypes have been identiﬁed in
diseased human heart valves [5], including quiescent ﬁbroblast-like
VICs (qVICs), which upon pathological cues can differentiate into
activated myoﬁbroblast-like VICs (aVICs); and osteoblast-like VICs
(oVICs), which are responsible for the active deposition of calcium
in CAVD [6e8]. Additionally, numerous studies have demonstrated
the ability of VICs to undergo osteogenic differentiation [9e11].
Relatively little is known about the role of VECs in CAVD. VECs cover
the surface of the heart valve to form an endothelial monolayer, and
are unique in that they can undergo endothelial-to-mesenchymal
transformation (EndMT) d a critical process in developmental
valvulogenesis [12e15]. During development, EndMT occurs in the
endocardial cushions, where a subset of endothelial cells detach
from the endothelium, transiently enhance the contractile protein
a-SMA, and migrate into the interstitium of the embryonic valve to
become VICs [13,16,17]. EndMT also occurs in adult valves, where
cells co-expressing endothelial markers and a-SMA have been
detected along the valve endothelium and in subendothelial loca-
tions [18]. These observations prompted the hypothesis that low or
basal levels of EndMT contribute to the replenishment of VICs as
part of physiologic valve remodeling that is required throughout
postnatal life [19]. We recently demonstrated that EndMT plays a
role in the adaptive pathologic remodeling of mitral valve leaﬂets in
an ovine model of functional mitral regurgitation [20,21]. In addi-
tion, EndMT has shown to be potentiated by exposure to cyclic
mechanical strain [22]. We furthermore showed that mitral VECs
are able to differentiate in vitro into mesenchymal lineages,
including osteogenic cells [14].
VECs have been indicated as key regulators in early CAVD via
recruitment of immune cells [23], dysregulation of protective nitric
oxide (NO) signaling [24,25], and phenotypic plasticity through the
expression of procalciﬁc proteins [14]. Collectively, these studies
indicate a potential role for dysregulated VECs in valvular disease,
but the role of EndMT in aortic valve leaﬂet calciﬁcation in CAVD is
yet unknown. Furthermore, factors that regulate EndMT-associated
VEC differentiation into osteogenic cells remain unclear. Based on
our previous investigations, we hypothesized that VECeVIC inter-
action serves as a native barrier to prevent excessive VEC EndMT
and subsequent osteogenic differentiation.
2. Methods
2.1. Aortic valve cell isolation
Ovine tissues from animals 8e10 months of age, weighing
20e25 kg, were obtained under approved NIH guidelines for ani-
mal experimentation as performed at Children's Hospital Boston.
Valve leaﬂets were incubated in endothelial basal medium (EBM-2)
(CC- 3156, Cambrex Bio Science, Walkersville, MD) with 5% fetal
bovine serum (FBS) (Hyclone, Logan, UT), 1% GPS (Invitrogen,
Carlsbad, California), 2 mmol/L L-glutamine, and 100 mg/ml genta-
micin sulfate for 1e4 h. They were then minced into 2-mm pieces
and incubated with 0.2% collagenase A (Roche Diagnostics, Indi-
anapolis, IN) in EBM-2 for 5 min at 37 C, and diluted with Hanks'
balanced salt solution containing 5% FBS, 1.26 mmol/L CaCl2,
0.8 mmol/L MgSO4, and 1% GPS (wash buffer). The supernatant was
sedimented at 200  g, resuspended in VEC medium (EBM-2 me-
dium, 10% heat-inactivated FBS, 1% GPS, and 2 ng/mL basic ﬁbro-
blast growth factor [bFGF]; Roche Diagnostics, Indianapolis, IN) and
plated. The following day, primary cultures were washed to remove
unattached cells. Primary cultures were trypsinized, resuspended
in growth medium at 3.3 cells/ml, and 100 ml were plated in eachwell of a 96-well plate, at a concentration of approximately one cell
to every third well; visual inspection was performed to assess that
single colonies appeared in a subset of wells. When the colonies
covered two-thirds of the well, cells were split into 24-well dishes.
Based onmorphology, these clones were initially visually identiﬁed
as either endothelial or interstitial. These observations were
conﬁrmed with phenotypic characterization and designated as
either endothelial (VEC) [26,27] or interstitial (VIC-K3, VIC-K5, VIC-
K6), and expanded on 1% gelatin-coated dishes in VEC media. Cells
were passaged 1:3 or 1:4 every 6e14 days, and experiments were
performed using VEC and VIC clones between passages 8 and 14.
VECs were grown in VEC media, and VICs were cultured in VIC
media (DMEM, 10% FBS, 1% GPS).
2.2. Human calciﬁed aortic valves
Aortic valve leaﬂets (n ¼ 5) were harvested from patients un-
dergoing aortic valve replacement for aortic valve stenosis and a
healthy valve was obtained from autopsy, performed using criteria
established by the declaration of Helsinki. Tissue samples were
frozen in optimal cutting temperature compound (OCT, Sakura
Finetech, Torrance, CA) and 7 mm serial sections were cut and
stained. Tissue was collected according to Brigham and Women's
Hospital IRB Protocols.
2.3. Mouse model of CAVD
Male apolipoprotein E-deﬁcient mice (apoE/ mice; 10 weeks
old) were purchased from Jackson Laboratory (Bar Harbor, ME).
High-fat diet (21% fat and 0.21% cholesterol) was obtained from
Research Diets (D12079B, New Brunswick, NJ). Mice were fed with
an atherogenic diet for a total of 22 weeks. Mice were euthanized
for tissue collection and histopathology at 32 weeks. The animal
procedures were performed conform the NIH guidelines and
approved by the Brigham and Women's Hospital Animal Care and
Use Committee. This model is characterized by the presence of
functional and histopathological changes found in human CAVD
[33].
2.4. Endothelial-to-mesenchymal transformation (EndMT)
EndMT was induced as described previously [27]. The assay was
also performed in the presence of VICs in an indirect co-culture
system, using a Transwell system (12-mm Transwells with 0.4-
mm pore polycarbonate membrane inserts; Corning Life Sciences,
Acton, MA) (Supplemental Fig. I). Brieﬂy, VECs were grown alone or
in co-culture with VICs in VEC media, or VEC media supplemented
with 2 ng/mL TGF-b1 (R&D Systems, Minneapolis, MN), for up to 14
days. Media was changed every 2e3 days.
2.5. VEC and VIC osteogenic potential
The osteogenic potential of VEC and VIC clones was tested both
separately and in co-culture for up to 21 days via treatment with
osteogenic media (OM) (DMEMwith 10% FBS,1% GPSwith 10 nmol/
L beta-glycerolphosphate, 50 mmol/L ascorbic acid, 10 mmol/L
dexamethasone). DMEM with 10% FBS, 1% GPS was used as control
medium (NM). Media was changed every 2e3 days.
2.6. VEC-VIC indirect co-culture
Co-culture experiments were performed using Transwell plates
(Corning, Tewksbury, MA) (Supplemental Fig. I). Cells were plated
either in the Transwell inserts or on the bottom of 6-well plates at a
density of 1  105 cells/cm2 and allowed to adhere overnight. After
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placing the inserts into the corresponding well of the 6 well plate.
For the conditioned media experiments, cells were treated with
media that had been conditioned by the speciﬁc cell type for 24 h.
Conditioned media was sterile-ﬁltered and added in a 1:1 ratio
with fresh media to treated cells. Media was changed every 2e3
days.
2.7. Histological detection of VEC and VIC mineralization
Upon completion of experiments, cells were washed with PBS
and ﬁxed using 4% paraformaldehyde for 15 min. Cells were sub-
sequently washed with PBS. Mineralization was analyzed by
staining with 0.02 mg/L of Alizarin Red S (SigmaeAldrich). The area
of positive Alizarin Red S staining was normalized to cell number.
To detect the expression of alkaline phosphatase (ALP), nitro-blue
tetrazolium/indolylphosphate (NBT/BCIP) staining was performed.
Before staining, the cells were washed with PBS, 0.5 ml of NBT/BCIP
was added, and the samples were then incubated at 37 C in a
humidiﬁed chamber containing 5% CO2 for 30 min. Samples were
then washed with PBS and ﬁxed with 4% PFA, after which they
underwent a counter stain with 0.1% eosin for 5 min. Images were
taken with an Eclipse 80i microscope (Nikon) and processed with
Elements 3.20 software (Nikon).
2.8. Alkaline phosphatase activity and calcium measurements
A colorimetric kit was used to measure ALP activity (BioVision,
Milpitas, CA) according to the manufacturer's instructions. 16 ml of
supernatant from 12-well plates was added to 64 ml of ALP assay
buffer and 50 ml of PnPP solutionwas added and incubated for 1 h at
room temperature. The absorbance was read at a wavelength of
405 nm. Values were normalized to the standard curve. Calcium
content was quantiﬁed using a colorimetric kit (BioVision) ac-
cording to the manufacturer's protocol. Brieﬂy, 50 mL of sample was
added to 60 mL of calcium assay buffer, after which 90 mL of chro-
mogenic reagent was added and incubated for 10 min at room
temperature in the dark. Absorbance was read at a wavelength of
575 nmwith a plate reader. Values were normalized to the standard
curve.
2.9. Immunoﬂuorescence and western blotting
Immunoﬂuorescence staining was performed on methanol-
ﬁxed cells and human and mouse aortic valve leaﬂets using anti-
human VE-cadherin (Santa Cruz) or CD31 (Cell Signaling), anti-
human a-SMA (clone 1A4, SigmaeAldrich), anti-vimentin anti-
body (Abcam, Cambridge, MA) and anti-osteocalcin (Abcam). Sec-
ondary antibodies conjugated with AlexaFluor 488 (Invitrogen)
were used. Images were taken with an Eclipse 80i microscope
(Nikon) and processed with Elements 3.20 software (Nikon). For
western blotting, cells were lysed as previously described [14].
Brieﬂy, cells were lysed with 4 mol/L urea, 0.5% SDS, 0.5% NP-40,
100 mmol/L Tris, and 5 mmol/L EDTA, pH 7.4, containing
100 mmol/L leupeptin 10mmol/L benazmidine,1 mmol/L PMSF, and
12.5 mg/mL aprotinin. Lysates were subjected to 10% SDS-PAGE
(13 mg of protein per lane) and transferred to Immobilon-P mem-
brane (Millipore, Bedford, MA). Membranes were incubated with
murine anti-human a-SMA, goat anti-human CD31, and goat anti-
human VE-Cadherin diluted in 5% dry milk in 1x PBS-T (0.1%
Tween-20, 25 mM Tris-HCL, 0.15 M NaCl in PBS), and then with
secondary antibody (peroxidase-conjugated anti-mouse or anti-
goat). AntigeneAb complexes were visualized using chemilumi-
nescent sensitive ﬁlm. Equal protein amounts (12e15 mg) were
loaded in each lane (determined by u-BCA assay, Pierce), andexpression was quantiﬁed via densitometry analysis and normal-
ized to that of b-actin (Sigma). All antibodies were shown to cross-
react with their ovine homologs.
2.10. Real-time polymerase chain reaction
Total RNA was isolated using RNeasy Mini Kit (Qiagen), sup-
plemented with DNase I treatment (Qiagen). Reverse transcription
was performed with Superscript II cDNA synthesis kit (Invitrogen/
Life Technologies, Grand Island, NY) to obtain a target cDNA con-
centration of 0.335 mg/mL, followed by RT-PCR using SYBR Green
(BioRad, Hercules, CA), and annealing temperatures of 95 C and
60 C for 35 cycles. Oligonucleotide primer sequences are presented
in Supplementary Table 1. All PCR products were sequenced using
ABi DNA sequences (Children's Hospital Boston core facility) to
verify the sequence corresponding to the gene of interest
(Supplementary Table 1).
2.11. Migration assay
100 mg/mL rat tail collagen type I (0.02 N acetic acid) was used to
coat 6.5-mm Transwells with 8.0-mm pore polycarbonate mem-
brane inserts for 1 h at 37 C, followed by one wash with PBS. Cells
were treated as speciﬁed, trypsinized, and seeded in the upper
chamber of the transwell plate at a density of 1  104 cells/well
(100 ml volume). 300 mL of control media (EBM-2/serum-free and
growth factor-free) or VEC media supplemented with 20% FBS was
added to the lower chamber. Cells were then allowed to migrate for
4 h at 37 C. The cells in the upper chamber were gently removed
using a cotton swab, and the lower surface was ﬁxed with ice-cold
methanol and mounted on glass slides in mounting media con-
taining DAPI. Cells were counted using a ﬂuorescent microscope.
2.12. Statistical analysis
Results are presented as mean ± standard deviation (SD) unless
indicated otherwise. Unpaired Student's t-test was used for com-
parisons between two groups. One-way ANOVA was used to eval-
uate statistical signiﬁcant differences in multiple groups. P < 0.05
was considered statistically signiﬁcant.
3. Results
3.1. TGF-b1 and osteogenic media induce VEC EndMT
Clonal populations from ovine aortic valve leaﬂets were isolated
using a brief collagenase-A procedure, which has been described
previously [12]. The VEC clone demonstrated cobblestone endo-
thelial morphology and stained positively for VE-Cadherin and
negatively for a-SMA (Supplementary Fig. II). VIC clonal pop-
ulations from the same valve were isolated and characterized.
Immunoﬂuorescence staining of the aortic VIC clones (VIC-K3, VIC-
K5, and VIC-K6) conﬁrmed the characteristic myoﬁbroblastic
phenotype of VICs grown in culture, with positive staining for a-
SMA and vimentin and negative staining for the endothelial cell
marker VE-Cadherin (Supplementary Fig. III).
In accordancewith our earlier work [12], this VEC clonewas able
to undergo TGF-b1-induced EndMT, as visualized by anti-a-SMA
immunoﬂuorescence after 8 days of TGF-b1 stimulation
(Supplementary Fig. IVA). Western blot analysis conﬁrmed the
changes in protein expression (Supplemental Fig. IVB). Signiﬁcant
increases in mRNA expression of the EndMT markers a-SMA
(5.3 ± 1.2), MMP-2 (13.5 ± 0.6) and Slug (12 ± 2.1), as well as a
decrease of the endothelial marker VE-Cadherin (0.2 ± 0.1)
(p < 0.05) conﬁrmed TGF-b1-induced EndMT of the VECs (n ¼ 3,
Fig. 1. AeC. EndMT may precede VEC osteoblastic differentiation. VECs (n ¼ 3) were treated with normal media (NM) or osteogenic media (OM) ± TGF-b1 for 1, 7 or 14 days. A:
Immunoﬂuorescence staining of VE-cadherin and a-SMA (green), cell nuclei (DAPI/blue). (n ¼ 3). Bar ¼ 50 mm. B: Quantiﬁcation of a-SMA staining. C: mRNA expression of a-SMA,
MMP-2 and Slug. Data is depicted as mean ± SD fold change, *p < 0.05. D: ALP staining of VECs in media þ TGF-b1 or OM at day 14. (n ¼ 3). Bar ¼ 50 mm. E: ALP activity of VECs in
media þ TGF-b1 or OM. Data is depicted as mean ± SD/normalized to NM conditions, *p < 0.05. F: mRNA expression of osteopontin, osteocalcin and Runx2. Data is depicted as
mean ± SD fold change, *p < 0.05.
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We performed a time-course analysis of EndMT-associated
proteins in VECs treated with either TGF-b1 or osteogenic media
(OM) for up to 14 days. VECs were stained for VE-cadherin and a-
SMA at days 1, 7, and 14 of culture (Fig. 1A). Both TGF-b1 and OM
induced a progressive loss of VE-cadherin compared to NM in the
VECs. Quantiﬁcation of a-SMA-positive cells conﬁrmed the increase
of myoﬁbroblast-like differentiation of VECs after day 7 and day 14,
as compared to day 1 (p < 0.05). When VECs were cultured in OM, a
higher percentage of a-SMA-positive cells were present on day 14,
as compared to day 7 (Fig. 1B). RT-PCR analysis of EndMT markers
revealed a signiﬁcant increase in mRNA expression of a-SMA at day
7 relative to day 1 when cultured with TGF-b1 (9.8 ± 4.3) and OM
(7.9 ± 1.1), but a-SMA expression decreased at day 14 as compared
to day 7 (Fig. 1C). In cells stimulated with TGF-b1 or OM, MMP-2
expression increased signiﬁcantly from day 7 (TGF-b1: 2.3 ± 0.5;
OM: 2.7 ± 1.1) to day 14 (TGF-b1: 5.4 ± 1.8; OM: 5.6 ± 0.7). Slug
expression follows a similar pattern to a-SMA, demonstrating a
signiﬁcant increase at day 7 (TGF-b1: 5.8 ± 1.9; OM: 6.4 ± 2.2)
compared to day 1 (p < 0.05). While day 14 for Slug was not
signiﬁcantly different from day 7, it remained signiﬁcantly
increased as compared to day 1 (TGF-b1: 4.1 ± 0.3; OM: 2.6 ± 0.7)
(Fig. 1C). The increase in expression of these EndMT markers be-
tween days 1 and 7 suggests that a process of EndMToccurs in both
the VECs treated with TGF-b1 and those treated with OM.
3.2. Osteogenic differentiation follows EndMT in VECs
We next evaluated osteogenic differentiation over time. WeFig. 2. VICs suppress TGF-b1-induced VEC EndMT. VECs (n ¼ 3) were co-cultured with VIC
noﬂuorescence staining of a-SMA (green), cell nuclei (DAPI/blue). (n ¼ 3). Bar ¼ 50 mm. B: W
SMA). C: mRNA expression of EndMT markers a-SMA, MMP-2 and Slug. Data is depicted adetected a small number of ALP-positive cells following 14 days of
stimulation with TGF-b1, but when VECs were cultured in OM, a
more pronounced ALP staining was observed (Fig. 1D). This
observation was conﬁrmed by quantiﬁcation of the ALP activity
(OM: 3.2 ± 0.8 vs. TGF-b1: 1.9 ± 0.4 (Fig. 1E). TGF-b1 signiﬁcantly
increased osteopontin (2.9 ± 0.6) osteocalcin (4.8 ± 0.5), and Runx2
(3.2 ± 0.5) mRNA expression (p < 0.05) at day 14 (Fig. 1F). In
addition, when we cultured VECs in OM, we found a signiﬁcant
increase in osteopontin (15.5 ± 8.1), osteocalcin (11.5 ± 4.3), and
Runx2 (6.7 ± 2.1) expression at day 14, as compared with earlier
time points (p < 0.05) (Fig. 1F).3.3. VICs suppress TGFb1-induced EndMT of VECs
The presence of VICs (in co-culture) attenuated TGF-b1-induced
EndMT. VICs suppressed TGF-b1-induced expression of a-SMA in
VECs, as demonstrated by immunoﬂuorescence staining (Fig. 2A)
and conﬁrmed by Western blot. Three different VIC clones sup-
pressed the EndMT marker a-SMA when the VECs were stimulated
with TGF-b1 (Fig. 2B, Supplementary Fig. V). VICs signiﬁcantly sup-
pressed the expression of three EndMT markers in TGF-b1 treated
VECs: a-SMA (0.1± 0.5), MMP-2 (0.1± 0.1) and Slug (0.2± 0.2) (three
different VIC clones, p < 0.05; Fig. 2CeE). A similar inhibition of
EndMTmarkers was observed when using VIC conditioned media at
a 1:1 ratio (Supplementary Fig. VI). The presence of VICs also
inhibited TGF-b1-induced migration potential of VECs that were ﬁrst
co-cultured with VICs and TGF-b1, as compared to VECs treated with
TGF-b1 alone (Supplementary Fig. VII).s (n ¼ 3) in a Transwell culture system and treated with TGF-b1 for 8 days. A: Immu-
estern blot for endothelial markers (VE-cadherin, CD31) and myoﬁbroblastic marker (a-
s mean ± SD fold change, *p < 0.05.
Fig. 3. VICs suppress OM-induced VEC osteogenesis. VECs were co-cultured with VICs in a Transwell culture system in osteogenic media (OM) for 21 days. AeB: Immunoﬂuo-
rescence staining of VE-cadherin (green), aSMA (green), cell nuclei (DAPI/blue), and Alizarin Red S (ARS) (red/orange). (n ¼ 3). Bar ¼ 50 mm. C: mRNA expression of VE-cadherin, D:
a-SMA, E: Osteocalcin, F: Osteopontin, G: Runx2. H: Calcium content. Data is depicted as mean ± SD fold change, *p < 0.05.
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VECs were cultured in OM to evaluate their osteogenic differ-
entiation capacity, using DMEM-based normal growth media (NM)
as a control. VECs cultured in OM for 21 days demonstrated a loss of
VE-Cadherin, compared with VECs cultured in NM (Fig. 3A).
Mineralized matrix, visualized using Alizarin Red S staining, was
observed after culturing VECs for 21 days in OM, but was not
detected in VECs cultured in NM (Fig. 3A). The presence of VICs (in
co-culture) prevented both the OM-mediated decrease in VE-
Cadherin and the increase in mineralized matrix (Fig. 3B). There
was no difference in cell number between groups (Supplementary
Fig. VIII). Analyses of mRNA expression at day 21 conﬁrmed the
inhibitory effect of VICs on the osteogenic differentiation of VECs.
VE-Cadherin expression decreased signiﬁcantly in VECs in OM
compared to NM (0.3 ± 0.2 p < 0.05). This decreasewas inhibited by
the presence of VICs in co-culture (0.8 ± 0.5) (Fig. 3C). Expression of
a-SMA increased when VECs were cultured in OM (17.3 ± 7.5,
p < 0.05), and this increasewasmitigated by the presence of VICs in
co-culture (1.3 ± 0.7) (Fig. 3D). VEC cultured in OM showed
increased expression of osteocalcin (8.6 ± 1.3, p < 0.05), osteo-
pontin (3.7 ± 0.3, p < 0.05) and Runx2 (5.5 ± 1.5, p < 0.05),
compared with cells cultured in NM (Fig. 3EeG). The co-culture of
VECs with VICs in OM abolished the induction of osteogenic dif-
ferentiation markers. A functional consequence of osteogenic dif-
ferentiation, calcium deposition, increased when VECs were
cultured in OM alone, but was signiﬁcantly impaired when VECswere co-cultured with VICs (OM: 4.2 ± 1.7 mg/mL, OM þ VICs:
1.9 ± 0.8 mg/mL, n ¼ 3, p < 0.05) (Fig. 3H).3.5. VECs do not suppress osteogenic differentiation of VICs
We evaluated whether VECs have a similar inhibitory effect on
the osteogenic differentiation of VICs. VICs cultured in OM for 21
days demonstrated mineralized matrix by Alizarin Red S staining
(Fig. 4A). When VICs were co-cultured with VECs in NM or OM, VICs
also stained positively for both a-SMA and calcium (Fig. 4B).
Expression of a-SMA increased in VICs cultured for 21 days in OM
(1.4 ± 0.3, p < 0.05) (Fig. 4C). VICs cultured in OM with VECs
demonstrated a signiﬁcant decrease in a-SMA expression (0.2 ± 0.1
p < 0.05). The mRNA expression of osteogenic differentiation
markers osteocalcin, osteopontin, and Runx2 and the activity of ALP
further revealed that VECs do not exhibit an inhibitory effect on VIC
osteogenic differentiation (Fig. 4DeF, Supplementary Fig. IX).
Functionally, we observed a signiﬁcant increase in VIC calcium
deposition in the co-culture samples (Fig. 4G).3.6. Human and mouse calciﬁed aortic valves leaﬂets demonstrate
EndMT
After observing EndMT in isolated aortic VECs, we evaluated the
presence of EndMT in human calciﬁed aortic valve leaﬂets. Using
immunoﬂuorescence we demonstrate co-expression of a-SMA and
CD31 (Fig. 5), conﬁrming the presence of EndMT in calciﬁc valves.
Fig. 4. VECs do not suppress OM-induced VIC osteogenesis. VICs (n ¼ 3) were co-cultured with VECs in a Transwell culture system in osteogenic media (OM) for 21 days. AeB:
Immunoﬂuorescence staining of Alizarin Red S (ARS, red/orange), aSMA (green), cell nuclei (DAPI/blue). (n ¼ 3). Bar ¼ 50 mm. C: mRNA expression of a-SMA, D: Osteocalcin, E:
Osteopontin, F: Runx2. G: Calcium content. Data is depicted as mean ± SD fold change, *p < 0.05.
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indicating a potential role for EndMT in human calciﬁc aortic valve
disease. Further, a-SMA was not observed in the endothelium of a
non-calciﬁed human aortic valve leaﬂets. To further evaluate the
in vivo relevance of EndMT in CAVD we assessed a-SMA expression
in the aortic valve of wild type and Apoe /mice, a commonmouse
model of cardiovascular calciﬁcation [33]. Increased expression of
a-SMA was observed in the endothelium of the Apoe / mice.
4. Discussion
We report that VICs can inhibit EndMT of VECs even when
stimulated with TGF-b1, a well-established inducer of EndMT
[12,13,19,28]. We have also demonstrated that VEC osteogenic dif-
ferentiation is inhibited by VICs when cultured in an osteogenic
environment. Conversely, in our study, VECs did not inhibit VIC
mineralization. In addition, we have shown that EndMT may pre-
cede VEC osteogenesis. Finally, EndMT was observed to co-express
with osteogenic markers in a mouse model of aortic valve calciﬁ-
cation and human aortic valves obtained from patients with calciﬁc
aortic valve disease. We thus propose that VECs contain the ca-
pacity to differentiate into endothelial-derived VICs (eVICs)
through an EndMT process. In certain disease conditions where
communication between VICs and VECs is disrupted, EndMT may
be promoted. EndMT-derived eVICs may populate the valve leaﬂetand differentiate into osteoblastic cells (oVICs), contributing to the
pathological remodeling observed in CAVD (Fig. 6).
This study builds on our previous work, in which we demon-
strated that VEC clones from ovine mitral valve leaﬂets might be a
source for osteoblastic VICs [14]. Endothelial osteoblastic differen-
tiation potential has been proposed in VECs [14], prostate tumor EC
[29], mutant ECs with constitutively active ALK2 [30] and in arterial
endothelial cells in matrix Gla protein-deﬁcient mice [31]. We
previously showed that the in vitro osteogenic differentiation po-
tential of mitral VEC corresponded with focal regions of osteogenic
endothelium in tethered mitral valves in vivo [20]. The role of the
endothelium in valve calciﬁcationwas also suggested by the ﬁnding
that the endothelial activation marker VCAM-1 expression corre-
lated with VIC osteoblastic differentiation in a model of aortic valve
stenosis [32]. This work also underscores the unique plasticity
within subsets of VECs, which is reﬂected not only in diseased
states but also in normal valve physiology, as evident by the co-
expression of CD31 and a-SMA in human fetal and postnatal
semilunar valves [19].
These ﬁndings have prompted our hypothesis that d when
needed d a progenitor-like subset of VECs can replenish the VIC
population via EndMT [14]. In turn, this transdifferentiation could
contribute to maintaining structural integrity and function of the
heart valve (Fig. 6). In normal valves, qVICs are activated by envi-
ronmental cues and can differentiate into myoﬁbroblast-like VICs
Fig. 5. Human and mouse aortic valves demonstrate EndMT. Human non-calciﬁed and calciﬁed aortic valves (n ¼ 6) stained for CD31, a-SMA and osteocalcin. Aortic root sections
from wild type (n ¼ 2) and apoE / mice (n ¼ 3) stained with CD31 and a-SMA. Representative images of the leaﬂets are shown. * Aortic side. Bar ¼ 20 mm.
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tive remodeling of the valve ECM through the secretion of various
cytokines [33,34], matrix metalloproteinases [35,36], and deposi-
tion of ECM proteins [34,37]. But when persistent activation of VICs
occurs, an excessive, lasting remodeling of the valve ECM may also
take place. Such a maladaptive process may lead to a pathological
disruption of the valve's normal connective tissue homeostasis,
leading to ﬁbrosis and eventual calciﬁcation by differentiation of
oVICs [38]. Although the role of VECs in CAVD remains to beFig. 6. Schematic depiction of cellular mechanism of the role of VECs in valvular osteogenes
responsible for functional remodeling of the heart valve ECM. The interplay between qVICs
stimulation, aVICs can further differentiate into osteoblastic VICs (oVICs), which responsib
interactions are disrupted as CAVD progresses, VECs can differentiate into endothelial-derive
calciﬁcation of the valve.elucidated, mounting evidence indicates that endothelial dysfunc-
tion correlates with such continuous maladaptive VIC activation
[38]. To our knowledge, the present work is the ﬁrst to investigate
VECeVIC direct interaction in relation to osteogenesis in an in vitro
culture model system. VICs in culture mostly demonstrate a
myoﬁbroblast-like phenotype attributed to the unnatural stiff
substrate of the tissue culture plates [39]. To what extent qVICs
affect VEC phenotype in co-culture remains to be elucidated. In the
current experimental setup, we cannot separate the cultureis. (i) Quiescent VICs (qVICs) differentiate into activated myoﬁbroblast-like VICs (aVICs),
and aVICs is thought to be the cornerstone of valve homeostasis. (ii) Upon pathological
le for calcium deposition in CAVD. (iii) VICs inhibit VEC EndMT. (iv) When VECeVIC
d VICs (eVICs) via EndMT. (v) eVICs may also differentiate into oVICs and contribute to
J. Hjortnaes et al. / Atherosclerosis 242 (2015) 251e260 259conditions to modulate VIC and VEC phenotypes independently.
Therefore, both VICs and VECs were cultured in an osteogenic
environment. This may be similar to the tissue, wherein both cell
types are likely exposed to pathologic stimuli simultaneously, but it
is possible that certain cues lead to phenotypic changes in only one
cell type (e.g., hemodynamic changes that affect VECs only). Future
studies may try to build on the current work to isolate changes in
each cell type.
It remains unclear how closely the EndMT we have observed in
VECs in vitro reﬂects the EndMT that occurs in vivo, either during
valve development or disease. As such, it is important to note that
although we demonstrate a correlation of EndMT and osteogenesis,
our in vivo results cannot offer a causal role for VEC EndMT in CAVD.
Our in vivo knowledge of valve EndMT mostly stems from end-
point analyses of human postnatal pulmonary valve specimens or
studies of the murine endocardial cushion [19], where hallmarks of
EndMT consist of a loss of cellecell contact in the EC monolayer;
increased expression of a-SMA, MMP-2, and Slug; and increased
cellular invasion. The present study conﬁrms that EndMT d as
determined by these hallmarks d can be simulated in vitro. [12]
Therefore, our current results build upon previous work suggest-
ing that EndMT plays an important role in the onset of CAVD. Aortic
VECs represent a cell population with the intrinsic plasticity to
differentiate into myoﬁbroblast-like aVICs, and further into
osteoblast-like oVICs. That both phenotypes have been shown to
possess the potential to contribute to the development of CAVD
underscores the importance of understanding the role of the
valvular endothelium in the disease process. Future studies may
use cell lineage tracing and cell fate models to determine the source
of cells that populate the aortic valve leaﬂet during tissue remod-
eling and pathogenesis [40]. By building a better understanding the
cellular contributions to the dynamic valve remodeling, speciﬁc
populations of cells may be targeted to control valvular homeo-
stasis and develop therapeutics for CAVD.
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